false 0001742927 0001742927 2021-12-08 2021-12-08 0001742927 rvph:CommonStockCustomMember 2021-12-08 2021-12-08 0001742927 rvph:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2021-12-08 2021-12-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT 
 
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 
 
Date of Report (Date of earliest event reported): December 8, 2021
 
REVIVA PHARMACEUTICALS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-38634
 
85-4306526
(State or Other Jurisdiction
of Incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
19925 Stevens Creek Blvd., Suite 100, Cupertino, CA
 
95014
(Address of Principal Executive Offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (408) 501-8881
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered or to be registered pursuant to Section 12(b) of the Act.  
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which
registered
Common Stock, par value $0.0001 per share
 
RVPH
 
Nasdaq Capital Market
Warrants to purchase one share of Common Stock
 
RVPHW
 
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
 
Emerging growth company ☒
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         ☐
 
 

 
Item 5.07 Submission of Matters to a Vote of Security Holders.
 
On December 8, 2021, Reviva Pharmaceuticals Holdings, Inc. (the “Company”) held its Annual Meeting of Stockholders. The stockholders of the Company acted upon the following proposals at the Annual Meeting: (1) proposal for the election of directors; and (2) proposal for the ratification of the appointment of Armanino LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2021. The final voting results were as follows:
 
1. The election of each of Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel and Les Funtleyder as directors to hold office for a term of one year, until their successor is duly elected and qualified or they are otherwise unable to complete their term.
 
The votes were cast for this matter as follows:
 
Nominees
 
Votes For
   
Votes Withheld
   
Broker Non-Votes
 
Laxminarayan Bhat
   
7,178,282
     
6,255
     
2,526,872
 
Parag Saxena
   
7,050,195
     
134,342
     
2,526,872
 
Richard Margolin
   
7,178,264
     
6,273
     
2,526,872
 
Purav Patel
   
7,178,279
     
6,258
     
2,526,872
 
Les Funtleyder
   
7,178,275
     
6,262
     
2,526,872
 
 
2. The proposal to ratify the appointment of Armanino LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2021 was approved based upon the following votes:
 
Votes For
   
Votes Against
   
Abstentions
   
Broker Non-Votes
 
 
9,503,916
     
6,831
     
200,662
     
0
 
 
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
REVIVA PHARMACEUTICALS HOLDINGS, INC.
     
Dated: December 10, 2021
By:
/s/ Narayan Prabhu
 
Name:
Title:
Narayan Prabhu
Chief Financial Officer
 
 
 
Tenzing Acquisition (NASDAQ:TZAC)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Tenzing Acquisition Charts.
Tenzing Acquisition (NASDAQ:TZAC)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Tenzing Acquisition Charts.